Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Lifecare AS ( (DE:LFC0) ).
Lifecare ASA has received confirmation from the Norwegian Medical Products Agency (NOMA) that its application for a first-in-human clinical study of its continuous glucose monitoring system is complete and validated. The scientific assessment phase has begun, with a standard handling time of 45 days, potentially extending by 20 days if needed. The pilot study, crucial for the company’s CE-marking trial and European market launch in 2027, is expected to start in Q1 2026.
More about Lifecare AS
Lifecare ASA is a MedTech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company focuses on utilizing osmotic pressure as a sensing principle, with technology suitable for monitoring various analytes in humans and pets.
Average Trading Volume: 386,507
Current Market Cap: NOK101.8M
See more insights into LFC0 stock on TipRanks’ Stock Analysis page.